All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

312

Reset

312 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • BEAM-101Phase 21 trial

    Beam Therapeutics Inc. · Sickle Cell Disease

  • BEAM-201Phase 21 trial

    Beam Therapeutics Inc. · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia

  • BG1805Phase 21 trial

    Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute

  • BI-1808Phase 21 trial

    BioInvent International AB · Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma

  • BMS-986458Phase 21 trial

    Bristol Myers Squibb · Relapsed/Refractory Non-Hodgkin Lymphoma

  • BMS-986470Phase 21 trial

    Bristol Myers Squibb · Anemia, Sickle Cell, Healthy Volunteers

  • BosmolisibBR101801Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Peripheral T Cell Lymphoma

  • BP1001Phase 21 trial

    Bio-Path Holdings, Inc. · Acute Myeloid Leukemia (AML)

  • BRL-101Phase 21 trial

    Bioray Laboratories · Beta-Thalassemia

  • BT02Phase 21 trial

    Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma

  • CART84Phase 21 trial

    Gyala Therapeutics · Acute Myeloblastic Leukaemia, Leukemia, T-Cell

  • CD38Phase 21 trial

    Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma

  • CFI-400945Phase 21 trial

    Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

  • CK0801Phase 21 trial

    Cellenkos, Inc. · Aplastic Anemia

  • CLN-049Phase 21 trial

    Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML

  • CSL889Phase 21 trial

    CSL Behring · Sickle Cell Disease Vaso-occlusive Crisis

  • CT071Phase 21 trial

    CARsgen Therapeutics Co., Ltd. · Multiple Myeloma, Primary Plasma Cell Leukemia

  • CTS3497Phase 21 trial

    CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma

  • CTX-712Phase 21 trial

    Chordia Therapeutics, Inc. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

  • Debio 1562MPhase 21 trial

    Debiopharm International SA · Acute Myeloid Leukemia

  • DISC-3405Phase 21 trial

    Disc Medicine, Inc · Polycythemia Vera (PV)

  • DS3790aPhase 21 trial

    Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma

  • EB103Phase 21 trial

    Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell

  • EMB07Phase 21 trial

    Shanghai EpimAb Biotherapeutics Co., Ltd. · Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07

  • EO2463Phase 21 trial

    Enterome · Follicular Lymphoma, Marginal Zone Lymphoma

  • EP0042Phase 21 trial

    Ellipses Pharma · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

  • Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial

    Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma

  • EX103Phase 21 trial

    Guangzhou Excelmab Inc. · CD20-positive Non-Hodgkin Lymphoma

  • Extended PhasePhase 21 trial

    Chengdu Zenitar Biomedical Technology Co., Ltd · Polycythemia Vera (PV)

  • F182112Phase 21 trial

    Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma

  • GB2064Phase 21 trial

    Galecto Biotech AB · Myelofibrosis

  • GPC-100Phase 21 trial

    GPCR Therapeutics, Inc. · Multiple Myeloma

  • GSK3174998Phase 21 trial

    GSK · Multiple Myeloma

  • GSK5926371Phase 21 trial

    GSK · Lymphoma, Non-Hodgkin

  • GT719Phase 21 trial

    Grit Biotechnology · Hematological Malignancy (Leukemia- Lymphoma)

  • HDM2005Phase 21 trial

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Diffuse Large B Cell Lymphoma (DLBCL)

  • HDP-101Phase 21 trial

    Heidelberg Pharma AG · Multiple Myeloma, Plasma Cell Disorder

  • HEC53856Phase 21 trial

    Sunshine Lake Pharma Co., Ltd. · Chemotherapy-induced Anemia, Non-Myeloid Malignancy

  • HMB-002Phase 21 trial

    Hemab ApS · Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2

  • HMPL-689Phase 21 trial

    Hutchmed · Relapsed/Refractory Lymphoma

  • HP-002Phase 21 trial

    Shanghai Helioson Pharmaceutical Co., Ltd. · B-Cell Non-Hodgkin Lymphoma

  • HuL001Phase 21 trial

    HuniLife Biotechnology, Inc. · Multiple Myeloma Refractory

  • HX111Phase 21 trial

    Hanx Biopharmaceuticals (Wuhan) Co., Ltd. · Solid Tumor and Lymphoma

  • ICP-490Phase 21 trial

    Beijing InnoCare Pharma Tech Co., Ltd. · Relapsed or Refractory Non-Hodgkin Lymphoma

  • IDP-023Phase 21 trial

    Indapta Therapeutics, INC. · NHL, Multiple Myeloma, Blood Cancer

  • IMT-009Phase 21 trial

    Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer

  • INCA000585Phase 21 trial

    Incyte · Immune Thrombocytopenia

  • ITU512Phase 21 trial

    Novartis · Sickle Cell Disease

  • JBI-802Phase 21 trial

    Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera

NewerPage 5 of 7Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.